<button id="eiezk"><video id="eiezk"></video></button>

產(chǎn)品名稱

SB 939 - Pracinostat

產(chǎn)品貨號

Axon 1777 CAS [929016-96-6] MF C20H30N4O2MW 358.48 Purity: 99% Soluble in DMSO Description Potent and oral inhibitor of histone deacetylase (HDAC), selective for class I, II and IV HDACs. SB939 shows significant antiproliferative activity against a wide variety of tumor cell lines, with high tumor exposure and efficacy in mouse models of colorectal cancer References Certificates Categories Extra info V Novotny-Diermary et al. SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer. Mol. Cancer Ther. 2010, 9(3), 642-652. ? V Novotny-Diermary et al. Pharmacodynamic evaluation of the target efficacy of SB939, an oral HDAC inhibitor with selectivity for tumor tissue. Mol. Cancer Ther. 2011, 10(7), 1207-1217. ? AR Razak et al. Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours. Br. J. Cancer. 2011, 104(5), 756-762. Certificate of Analysis Material Safety Data Sheet Apoptosis Cell Cycle Regulation Cell Signaling & Oncology Epigenetics DNA-damage Response EC 3.5.1.98 HDAC HDAC inhibitor (1, 2, 4 Selective) Chemical name (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide Parent CAS No. [929016-96-6] Order Size Unit Price Stock 5 mg €95.00 In Stock

產(chǎn)品價(jià)格

現(xiàn)貨詢價(jià)，電話：010-67529703

產(chǎn)品規(guī)格

產(chǎn)品品牌

axonmedchem

產(chǎn)品概述

產(chǎn)品詳情

SB 939 - Pracinostat

Based on 16 reference(s) in Google Scholar 9 10 16

Axon 1777

CAS [929016-96-6]

MF C20H30N4O2
MW 358.48

Purity: 99%
Soluble in DMSO

SB 939

Description

Potent and oral inhibitor of histone deacetylase (HDAC), selective for class I, II and IV HDACs. SB939 shows significant antiproliferative activity against a wide variety of tumor cell lines, with high tumor exposure and efficacy in mouse models of colorectal cancer

V Novotny-Diermary et al. SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer. Mol. Cancer Ther. 2010, 9(3), 642-652.

V Novotny-Diermary et al. Pharmacodynamic evaluation of the target efficacy of SB939, an oral HDAC inhibitor with selectivity for tumor tissue. Mol. Cancer Ther. 2011, 10(7), 1207-1217.

AR Razak et al. Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours. Br. J. Cancer. 2011, 104(5), 756-762.

Certificate of Analysis
Material Safety Data Sheet

Apoptosis Cell Cycle Regulation Cell Signaling & Oncology Epigenetics DNA-damage Response EC 3.5.1.98 HDAC

HDAC inhibitor (1, 2, 4 Selective)

Chemical name

(E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide

Parent CAS No.

[929016-96-6]

產(chǎn)品資料

<button id="eiezk"><video id="eiezk"></video></button>